Madrigal Pharmaceuticals Stock Today
| MDGL Stock | USD 228.34 4.64 1.99% |
Performance2 of 100
| Odds Of DistressLess than 10
|
Madrigal Pharmaceuticals is selling for 228.34 as of the 18th of April 2024. This is a -1.99 percent decrease since the beginning of the trading day. The stock's lowest day price was 224.39. Madrigal Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Madrigal Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of February 2007 | Category Healthcare | Classification Health Care |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania. The company has 20.97 M outstanding shares of which 3.36 M shares are now shorted by private and institutional investors with about 4.79 trading days to cover. More on Madrigal Pharmaceuticals
Moving against Madrigal Stock
| 0.68 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Madrigal Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Madrigal Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Madrigal Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO, Director | Chen Schor | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation Analysts covering Madrigal Pharmaceuticals report their recommendations after researching Madrigal Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Madrigal Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Madrigal Pharmaceuticals. The Madrigal consensus assessment is calculated by taking the average forecast from all of the analysts covering Madrigal Pharmaceuticals. | |||||
Madrigal Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Madrigal Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Madrigal Pharmaceuticals' financial leverage. It provides some insight into what part of Madrigal Pharmaceuticals' total assets is financed by creditors.
| |||||
Madrigal Pharmaceuticals (MDGL) is traded on NASDAQ Exchange in USA. It is located in Four Tower Bridge, West Conshohocken, PA, United States, 19428 and employs 376 people. Madrigal Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 4.89 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Madrigal Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Madrigal Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Madrigal Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 20.97 M outstanding shares of which 3.36 M shares are now shorted by private and institutional investors with about 4.79 trading days to cover.
Madrigal Pharmaceuticals currently holds about 211.77 M in cash with (324.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.38.
Check Madrigal Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationMadrigal Pharmaceuticals holds a total of 20.97 Million outstanding shares. The majority of Madrigal Pharmaceuticals outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Madrigal Pharmaceuticals to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Madrigal Pharmaceuticals. Please pay attention to any change in the institutional holdings of Madrigal Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Also note that almost eight hundred thirty-eight thousand eight hundred sixty-four invesors are currently shorting Madrigal Pharmaceuticals expressing very little confidence in its future performance.
Check Madrigal Ownership Details
Madrigal Stock Price Odds Analysis
Proceeding from a normal probability distribution, the odds of Madrigal Pharmaceuticals jumping above the current price in 90 days from now is about 68.1%. The Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.783. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Madrigal Pharmaceuticals will likely underperform. Additionally, madrigal Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Madrigal Pharmaceuticals to move above the current price in 90 days from now is about 68.1 (This Madrigal Pharmaceuticals probability density function shows the probability of Madrigal Stock to fall within a particular range of prices over 90 days) .
Madrigal Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Madrigal Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Madrigal Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Madrigal Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Geode Capital Management, Llc | 2023-12-31 | 336.3 K | |
| Bain Capital Life Sciences Investors, Llc | 2023-12-31 | 324.6 K | |
| Artisan Partners Limited Partnership | 2023-12-31 | 296.5 K | |
| Citadel Advisors Llc | 2023-09-30 | 276.8 K | |
| Jane Street Group, Llc | 2023-12-31 | 216.8 K | |
| Alpinvest Partners N.v. | 2023-12-31 | 211.5 K | |
| Ra Capital Management, Llc | 2023-12-31 | 204.5 K | |
| Rock Springs Capital Management Lp | 2023-12-31 | 198.2 K | |
| Group One Trading, Lp | 2023-12-31 | 191.9 K | |
| Hhg Plc | 2023-12-31 | 2.9 M | |
| Baker Bros Advisors Lp | 2023-12-31 | 2 M |
Madrigal Pharmaceuticals Historical Income Statement
Madrigal Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Madrigal's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Madrigal Pharmaceuticals revenue and expense. Madrigal Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Madrigal Pharmaceuticals' Total Other Income Expense Net is quite stable compared to the past year. Selling General Administrative is expected to rise to about 113.6 M this year, although the value of EBIT is projected to rise to (361.5 M). View More FundamentalsMadrigal Stock Against Markets
Picking the right benchmark for Madrigal Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Madrigal Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Madrigal Pharmaceuticals is critical whether you are bullish or bearish towards Madrigal Pharmaceuticals at a given time. Please also check how Madrigal Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Madrigal Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Backtesting Now
Portfolio BacktestingAvoid under-diversification and over-optimization by backtesting your portfolios |
| All Next | Launch Module |
Madrigal Pharmaceuticals Corporate Directors
Madrigal Pharmaceuticals corporate directors refer to members of a Madrigal Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Madrigal Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Madrigal Pharmaceuticals' board members must vote for the resolution. The Madrigal Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Milligan | Independent Director | Profile | |
| Richard Levy | Director | Profile | |
| William Reardon | Independent Director | Profile | |
| James Daly | Independent Director | Profile |
How to buy Madrigal Stock?
Before investing in Madrigal Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Madrigal Pharmaceuticals. To buy Madrigal Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Madrigal Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Madrigal Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Madrigal Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Madrigal Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Madrigal Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Madrigal Stock please use our How to Invest in Madrigal Pharmaceuticals guide.
Already Invested in Madrigal Pharmaceuticals?
The danger of trading Madrigal Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Madrigal Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Madrigal Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Madrigal Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Madrigal Pharmaceuticals is a strong investment it is important to analyze Madrigal Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Madrigal Pharmaceuticals' future performance. For an informed investment choice regarding Madrigal Stock, refer to the following important reports: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Madrigal Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. For more information on how to buy Madrigal Stock please use our How to buy in Madrigal Stock guide.Note that the Madrigal Pharmaceuticals information on this page should be used as a complementary analysis to other Madrigal Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Madrigal Stock analysis
When running Madrigal Pharmaceuticals' price analysis, check to measure Madrigal Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Madrigal Pharmaceuticals is operating at the current time. Most of Madrigal Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Madrigal Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Madrigal Pharmaceuticals' price. Additionally, you may evaluate how the addition of Madrigal Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Madrigal Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Madrigal Pharmaceuticals. If investors know Madrigal will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Madrigal Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (19.99) | Return On Assets (0.47) | Return On Equity (1.24) |
The market value of Madrigal Pharmaceuticals is measured differently than its book value, which is the value of Madrigal that is recorded on the company's balance sheet. Investors also form their own opinion of Madrigal Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Madrigal Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Madrigal Pharmaceuticals' market value can be influenced by many factors that don't directly affect Madrigal Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Madrigal Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Madrigal Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Madrigal Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.